Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vertiv Holdings Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Vertiv Holdings Co trades at $313.6 (market cap $122.48B). The key difference: Vertiv Holdings Co is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Vertiv Holdings Co pays a 0.08% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VRT | |
|---|---|---|
Market Cap | $39.89B | $122.48B |
Sector | Health | Technology |
52-Week High | $491.22 | $376.23 |
52-Week Low | $278.09 | $121.82 |
Enterprise Value | $38.15B | $123.24B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VRT trades at $318.86, down 1.56% today, but maintains a bullish technical stance with strong support at $318. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.17 exceeding the $1.00 estimate. Revenue growth is solid, projected to rise from $10.23B in 2025 to $10.8B in 2026, while net income margins expand from 13.02% to 14.37%.
Outlook remains positive driven by AI infrastructure demand, though premium valuations (P/E 80.12) pose risks. Analyst consensus is strongly bullish with a $395.23 price target. Key risks include execution challenges in capacity expansion and competitive pressures in the cooling solutions market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
